Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Ryan S. Jackson

Otolaryngology
Washington University
4921 Parkview Pl, Suite 11a, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
17 Years of Experience
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Washington University
4921 Parkview Pl, Suite 11a, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ryan Jackson is an Otolaryngologist in Saint Louis, Missouri. Dr. Jackson has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Laryngeal Cancer, Laryngectomy, and Gastrostomy. Dr. Jackson is currently accepting new patients.

His clinical research consists of co-authoring 140 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 34 articles and participated in 3 clinical trials in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Graduate Year
2009
Specialties
Otolaryngology
Licenses
Otolaryngology in MO
Hospital Affiliations
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Suite 11a, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Cisplatin, Pembrolizumab
Study Phase: Phase 2
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drug: Paclitaxel
Study Phase: Phase 1/Phase 2
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drug: Cisplatin
Study Phase: Phase 2
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Palbociclib, Cetuximab, Cisplatin
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: November 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
Evaluation of TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers: a Pilot Study
Evaluation of TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers: a Pilot Study
Enrollment Status: Terminated
Publish Date: July 12, 2022
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of Fluorescence Imaging in Head and Neck Cancer
Evaluation of Fluorescence Imaging in Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 18, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 7 Less Clinical Trials
Similar Doctors
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Brian Nussenbaum
Otolaryngology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Brian Nussenbaum
Otolaryngology
4921 Parkview Pl, Ste 11a, 
Saint Louis, MO 
 (0.1 miles away)
314-362-7509
Languages Spoken:
English
See accepted insurances

Brian Nussenbaum is an Otolaryngologist in Saint Louis, Missouri. Dr. Nussenbaum is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Thyroid Cancer, Laryngectomy, and Gastrostomy.

Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Sidharth V. Puram
Otolaryngology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Sidharth V. Puram
Otolaryngology

Washington University

660 S Euclid Ave Box, 8115 Dept Of Otolaryngolog, 
Saint Louis, MO 
 (0.9 miles away)
314-362-7509
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

Sidharth Puram is an Otolaryngologist in Saint Louis, Missouri. Dr. Puram is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Laryngectomy, and Glossectomy. Dr. Puram is currently accepting new patients.

Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Patrik J. Pipkorn
Otolaryngology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Patrik J. Pipkorn
Otolaryngology

Washington University

4921 Parkview Pl, Suite 11a, 
Saint Louis, MO 
 (0.1 miles away)
314-362-7509
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrik Pipkorn is an Otolaryngologist in Saint Louis, Missouri. Dr. Pipkorn is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngectomy, and Gastrostomy. Dr. Pipkorn is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jackson's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 12 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile